D.A. Davidson & CO. Cuts Stock Position in IQVIA Holdings Inc. $IQV

D.A. Davidson & CO. cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 18.1% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 22,261 shares of the medical research company’s stock after selling 4,929 shares during the period. D.A. Davidson & CO.’s holdings in IQVIA were worth $3,796,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of IQVIA by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock worth $4,429,426,000 after purchasing an additional 159,899 shares during the last quarter. Geode Capital Management LLC boosted its holdings in IQVIA by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock worth $982,272,000 after buying an additional 24,453 shares during the last quarter. Boston Partners increased its stake in IQVIA by 14.9% during the 4th quarter. Boston Partners now owns 4,087,380 shares of the medical research company’s stock worth $923,276,000 after buying an additional 530,672 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of IQVIA by 16.2% during the fourth quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock valued at $856,468,000 after acquiring an additional 528,753 shares during the last quarter. Finally, Invesco Ltd. lifted its position in shares of IQVIA by 15.3% in the third quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock valued at $526,891,000 after acquiring an additional 367,204 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on IQV. Robert W. Baird boosted their price target on IQVIA from $230.00 to $249.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 1st. Weiss Ratings upgraded IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday. Wall Street Zen cut shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Evercore reaffirmed an “outperform” rating and set a $185.00 target price on shares of IQVIA in a report on Wednesday, April 8th. Finally, Mizuho raised their price target on shares of IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Fourteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $225.71.

IQVIA Price Performance

NYSE:IQV opened at $206.26 on Monday. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $247.04. The stock has a market cap of $34.42 billion, a PE ratio of 25.56, a P/E/G ratio of 1.85 and a beta of 1.20. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. The stock has a 50 day moving average price of $185.04 and a 200 day moving average price of $187.88.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The company had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities research analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA announced that its board has initiated a stock buyback program on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its shares are undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.